Metformin sensitizes human breast cancer MDA-MB-231 cells to tamo-xifen through down-regulation of c-Myc

AIM: To investigate whether metformin enhances the sensitivity of human breast cancer MDA-MB-231 cells to tamoxifen by down-regulating c-Myc. METHODS: The cell viability, colony formation, apoptosis, and migration and invasion abilities of MDA-MB-231 cells were detected by CCK-8 assay, colony formation experiment, flow cytometry and Transwell assay. The expression level of c-Myc was quantified by Western blot and immunohistochemical analysis. The antitumor effects of metformin and tamoxifen were investigated in vivo in a MDA-MB-231 triple-negative breast cancer xenograft model in the SCID mice. RESULTS: Metformin in combination with tamoxifen exerted synergistic effects on inhibition of the viability, colony formation, migration and invasion, and induced the apoptosis compared with the controls and either agent treatment alone in the MDA-MB-231 cells. The levels of c-Myc was down-regulated in vitro by treatment with metformin and/or tamoxifen (P<0.01). Moreover, metformin or in combination with tamoxifen also reduced the growth of MDA-MB-231 breast cancer tumors in the SCID mice by down-regulation of c-Myc in vivo. CONCLUSION: Metformin in combination with tamoxifen exerts synergistic effects on inhibition of the proliferation, migration, invasion and tumor growth of human triple-negative breast cancer MDA-MB-231 cells by down-regulating c-Myc expression, suggesting that metformin in combination with tamoxifen merits further evaluation as a target.     

Effects of cinnamyl aldehyde on c-Fos and c-Myc expression in NIH3T3 cells

AIM: Cinnamyl aldehyde (CA) is one alcohol ingredient derived from Cinnamomum cassia,which is widely used in treating chronic skin wound in Chinese medicine with the curative effect of ‘rescuing YANG’.The purpose of the present study was to investigate the expression of c-Fos,c-Myc proteins at different time points in NIH3T3 treated with CA and explore the possible mechanism of promoting cell proliferation by CA.METHODS: MTT assay was used for observing cell proliferation.Expression of c-Fos and c-Myc proteins in NIH3T3 cells were assessed by immunocytochemistry assay.RESULTS: The cell proliferation was promoted obviously when CA concentration was between 8.8×10^-2 μg/L and 8.8×10 μg/L.CA at concentration of 5.5 μg/L significantly induced expression of c-Fos,c-Myc proteins at 2-3 h after the stimulation compared with control group (P<0.01).CONCLUSION: CA increases expression of c-Fos and c-Myc proteins,which may be one of mechanisms for CA to promote NIH3T3 cell proliferation.     

Inhibition of c-Myc by 10058-F4 overcomes imatinib resistance in chronic myeloid leukemia cells

AIM：To investigate the effect of c-Myc inhibitor 10058-F4 on human chronic myeloid leukemia (CML) K562 cells and imatinib-resistant K562/G cells. METHODS：The protein expression of c-Myc was detected by Western blotting. Cell proliferation was evaluated by MTT assay and colony formation assay. PI staining was used to determine the cell cycle distribution. Annexin V-PI staining was applied for apoptosis detection. RESULTS：Imatinib-resistant K562/G cells displayed lower sensitivity to imatinib than K562 cells with high expression of c-Myc. Treatment with specific c-Myc inhibitor 10058-F4 inhibited the cell proliferation in a dose- and time-dependent manner, and K562/G displayed more sensitivity to 10058-F4 than K562 cells. 10058-F4 also induced cell cycle arrest in G0/G1 phase and induced apoptotic cell death in the 2 cells. Importantly, 10058-F4 suppressed the colony formation ability in K562 and K562/G cells. CONCLUSION：c-Myc is a novel target to overcome imatinib-induced drug resistance, and c-Myc inhibitor provides a new approach in CML therapy.     

mTOR kinase inhibitor CC-223 suppresses human breast cancer cell viability

AIM: To investigate the inhibitory effect of CC-223, an inhibitor of mammalian target of rapamycin (mTOR) kinase, on the viability of human breast cancer cells and its mechanism. METHODS: The inhibitory effect of CC-223 on the viability of MCF-7 cells and MDA-MB-231 cells was measured by CCK-8 assay. The cell cycle distribution of breast cancer cells was examined by flow cytometry. The expression of cell cycle-related proteins and oncoproteins c-Myc and survivin was analyzed by Western blot. RESULTS: CC-223 significantly inhibited the viability of both MCF-7 and MDA-MB-231 cells (P<0.05). CC-223 induced cell cycle arrest in both G₁ phase and G₂/M phase in the MCF-7 cells (P<0.05). However, low concentration of CC-223 treatment resulted in the accumulation of MDA-MB-231 cell cycle in the G₂/M phase, and the cell number in G₁ phase was unaffected. Treatment with CC-223 for 24 h clearly inhibited the protein levels of cyclin B1, cyclin D1 and phosphorylated cell division cycle protein 2 in the breast cancer cells (P<0.05). CC-223 suppressed the expression of c-Myc and survivin in both MCF-7 cells and MDA-MB-231 cells (P<0.05). CONCLUSION: CC-223 inhibits cell viability by blocking cell cycle progression and down-regulating expression of c-Myc and survivin in both MCF-7 and MDA-MB-231 cells.     

Effects of up-regulation of c-myc expression on U937 cell line

AIM:To establish a human monocytic　leukemia cell line U937 stably expressing c-myc gene and to investigate the biological characteristics of this cell line. METHODS:The recombinant plasmid MSCV-c-myc-IRES-GFP (MMIG) was constructed. MMIG and MSCV-IRES-GFP (MIG) were used to package the viruses for infecting U937 cells. Fluorescence-activated cell sorter (FACS) was used for sorting U937/GFP and U937/MYC cells. The GFP-positive cells were detected by fluorescence microscopy and FACS. The protein expression of c-Myc, survivin, X-linked inhibitor of apoptosis protein (XIAP) and Bcl-2 was detected by Western blotting. Cell proliferation was evaluated by MTT assay. Propidium iodide (PI) staining was used to determine the cell cycle distribution. Self-renewal ability was observed by colony- forming assay. RESULTS:The GFP expression in the cells infected with MIG or MMIG virus was observed under fluorescence microscope. The green fluorescent rate of the cells infected with MIG was 26.0%, while that of the cells infected with MMIG was 27.7%. The protein expression of c-Myc in MMIG-infected U937 cells was higher than that in MIG-infected cells. After sorting, the green fluorescent rates of U937/GFP and U937/MYC cells reached 98.7% and 93.7%, respectively. The protein expression of c-Myc in U937/MYC cells was higher than that in U937/GFP cells. In addition, survivin, a downstream protein of c-Myc, was up-regulated, while the protein expression of XIAP and Bcl-2 remained unchanged. Cell cycle analysis showed that the percentage of the cells in S phase increased in U937/MYC cells. Moreover, the proliferation and colony-forming ability of U937/MYC cells were also enhanced. CONCLUSION: U937/MYC cell line stably expressing c-myc gene was successfully established. c-Myc may increase cell viability via enhancing the expression of anti-apoptotic protein survivin, the cell cycle transition and the self-renewal ability.     

High mobility group box 1 protein promotes proliferation,migration and invasion of colon cancer cells

AIM: To investigate the expression of high mobility group box 1 protein (HMGB1) in colon can-cer cells, and to determine its regulatory roles in colon cancer cell proliferation, migration and invasion. METHODS: qPCR and Western blot were used to quantify the mRNA and protein expression levels of HMGB1 in human colon cancer SW620 cells and normal colonic epithelial FHC cells. HMGB1 shRNA was transfected into the SW620 cells to establish the stable HMGB1-downregulating colon cancer cells (shHMGB1 group), and negative control (shNC) group and blank control (blank) group were also set up. The proliferation, migration and invasion of the cells were determined by CCK-8 assay, colony formation experiment and Transwell chamber assays. Western blot was used to determine the protein levels of p-ERK, ERK, c-Myc, matrix metalloproteinase (MMP)-2/9, E-cadherin, N-cadherin, Bcl-2 and Bax. RESULTS: Both of the mRNA and protein levels of HMGB1 in colon cancer cells were higher than those in the normal colonic epithelial cells (P<0.05). HMGB1 gene was successfully knocked down in SW620 cells. Compared with blank group and shNC group, the proliferation, migration and invasion abilities of the cells in shHMGB1 group were significantly inhibited (P<0.05). The protein levels of MMP-2, MMP-9, N-cadherin, c-Myc, Bcl-2 and p-ERK were reduced notably, while the expression of Bax protein was increased (P<0.05) in shHMGB1 group compared with shNC group and blank group.CONCLUSION: HMGB1 effectively promotes the proliferation, migration and invasion of colon cancer cells through ERK/c-Myc signaling pathway.     

皮肤特异表达c-Myc转基因小鼠的建立与分析

以CMV-PAAV载体为基础载体,以皮肤特异人K14（人角蛋白14）基因启动子替换原质粒中的CMV启动子后,在其多克隆位点区依次插入鼠c-Myc基因的cDNA序列和gfp基因的编码序列,构建了高效表达c-Myc基因的真核表达载体。通过双原核显微注射技术,将线性化的载体DNA注入到C57BL/6小鼠受精卵的两个原核中,然后将注射后状态良好的胚胎移植到代孕鼠的输卵管中,共移植了256枚受精卵,6只受体怀孕,最终获得44只成年小鼠。通过PCR和Southern blot分析证明2只为阳性转基因小鼠,转基因阳性率为4%。Southern杂交结果分析显示外源片断是以多拷贝串联重复的形式整合到鼠染色体中     

绵羊c-Myc与EGFP融合蛋白的真核表达及其对细胞增殖的调控作用

为了探讨c-Myc基因对细胞增殖及相关基因表达的调控作用，本试验构建了c-Myc-（G₄S）₃-EGFP融合基因的真核表达载体pc-Myc-EGFP，并利用生物信息学分析了其结构和理化特征。转染后分别通过细胞计数和qRT-PCR检测了其对绵羊胚胎成纤维细胞（sheep embryonic fibroblasts，SEF）增殖及相关基因表达的影响，并利用启动子分析软件解析了相应的表达调控机制。酶切鉴定和测序结果表明，载体构建成功。生物信息学分析表明，绵羊c-Myc蛋白主要定位于细胞核，含有螺旋环螺旋（helix-loop-helix，HLH）结构域，其分子量为48 474.78 u。融合蛋白c-Myc-（G₄S）₃-EGFP有较强的亲水性，且含有31个磷酸化位点。因（G₄S）₃有较高的灵活度（9.848 5），两侧的c-Myc和EGFP都保持各自的空间构象且互不干扰。进一步的细胞试验结果表明，重组质粒pc-Myc-EGFP在SEF中能够表达。过表达c-Myc促进了SEF的增殖，使cyclin D2、Cdk4、Cdk6、cyclin E1、cyclin A2、cdc25A mRNA的表达水平分别升高至5.20、3.10、6.54、6.52、23.37和8.22倍（P<0.01），E2F1 mRNA的表达升高至1.83倍（P<0.05）。启动子分析结果表明，各基因的5'调控区存在c-Myc和E2F1的结合元件。综上所述，绵羊c-Myc通过上调细胞周期相关基因的表达促进SEF细胞增殖，c-Myc的作用机制可能是通过直接作用于靶基因5'调控区的E-box元件，也可能是通过其他转录因子（如E2F1）的间接调控作用而实现。